scholarly journals De novo Glomerular Disease and the Significance of Electron Microscopy in Renal Transplantation

2021 ◽  
pp. 1-13
Author(s):  
Surya V. Seshan ◽  
Steven P. Salvatore

<b><i>Background:</i></b> De novo glomerular diseases comprising those both common and unique to transplant may develop in the renal allograft leading to posttransplant proteinuria, hematuria, or allograft failure. Electron microscopy (EM) is a useful adjunct to the standard light and immunofluorescence microscopy for accurately diagnosing these diseases and subsequently aiding the clinician in initiating appropriate treatments. <b><i>Summary:</i></b> De novo diseases are those new-onset diseases in renal transplantation that are unrelated to the original kidney disease in the recipient. They include virtually any primary or secondary glomerular, tubulointerstitial, or vascular diseases, ranging from subclinical to clinically overt, having acute, subacute, or chronic clinical presentations. This review focuses on common or significant, mainly glomerular, entities, with particular attention to the EM findings. The time of onset, stage, and severity of these diseases may often be modified by the current immunosuppressive protocols and other donor and recipient predisposing characteristics. <b><i>Key Messages:</i></b> A renal allograft biopsy not only improves our understanding of the pathophysiology but also provides diagnostic accuracy prognostic information, and potential for reversibility. In some cases, the biopsy leads to detection of unsuspected or clinically asymptomatic de novo diseases in the setting of other concomitant rejection processes, infection, or toxicity, which can dictate appropriate therapy. Routine EM in transplant kidney biopsies is a valuable modality in recognizing fully developed or early/subtle features of evolving de novo diseases, often during the subclinical phases, in “for cause” or surveillance/protocol allograft biopsies.

2021 ◽  
pp. 1-32
Author(s):  
Surya V. Seshan ◽  
Steven P. Salvatore

<b><i>Background:</i></b> The common causes of renal transplant complications include active or chronic rejection process, infections, and toxicity but also recurrent or de novo diseases, which play an important role in affecting long-term graft function or graft loss. <b><i>Summary:</i></b> Recurrent disease in renal transplantation is defined as recurrence of the original kidney disease leading to end-stage kidney disease. They comprise a heterogeneous group of predominantly glomerular and some tubulointerstitial and vascular lesions, which include primary kidney diseases (e.g., focal segmental glomerulosclerosis, membranous glomerulonephritis, and IgA nephropathy) or those secondary to systemic autoimmune, metabolic, and infectious processes that can range from subclinical to clinically overt acute, subacute, or chronic clinical presentations. In addition to the knowledge of prior renal disease and routine/periodic serum and urine testing for kidney function, a complete transplant renal biopsy examination is essential in the identification and differentiation of these diseases. The time of onset and severity of these diseases depend on the underlying etiopathogenetic mechanisms and the varied rates of recurrence in the early or late posttransplant period, often being modified by the current immunosuppressive protocols and other donor and recipient predisposing characteristics. <b><i>Key Messages:</i></b> Transplant kidney biopsy findings provide diagnostic accuracy and prognostic information regarding the potential for reversibility along with detection of unsuspected or clinically symptomatic recurrent diseases, with any concomitant rejection process or toxicity, for appropriate therapeutic decision-making. Routine electron microscopy in transplant kidney biopsies is a valuable tool in recognizing fully developed or early/subtle features of evolving recurrent diseases, often during the subclinical phases, in for cause or surveillance allograft biopsies.


1998 ◽  
Vol 65 (Supplement) ◽  
pp. 240
Author(s):  
S. Hariharan ◽  
C. Pelz ◽  
V. George ◽  
M. B. Adams ◽  
D. Brennan ◽  
...  

1998 ◽  
Vol 65 (12) ◽  
pp. S149
Author(s):  
A. W. Piering ◽  
D. Brennan ◽  
R. Ouseph ◽  
F. Vincenti ◽  
C. Davis ◽  
...  

1999 ◽  
Vol 31 (1-2) ◽  
pp. 223-224 ◽  
Author(s):  
S Hariharan ◽  
M.B Adams ◽  
D.C Brennan ◽  
C.L Davis ◽  
M.R First ◽  
...  

2014 ◽  
Vol 9 (8) ◽  
pp. 1479-1487 ◽  
Author(s):  
Claudio Ponticelli ◽  
Gabriella Moroni ◽  
Richard J. Glassock

1998 ◽  
Vol 65 (Supplement) ◽  
pp. 225
Author(s):  
A. W. Piering ◽  
D. Brennan ◽  
R. Ouseph ◽  
F. Vincenti ◽  
C. Davis ◽  
...  

2019 ◽  
Vol 8 (8) ◽  
pp. 1164 ◽  
Author(s):  
Hannes Neuwirt ◽  
Irmgard Leitner-Lechner ◽  
Julia Kerschbaum ◽  
Michael Ertl ◽  
Florian Pöggsteiner ◽  
...  

Belatacept is an attractive option for immunosuppression after renal transplantation. Renal allograft function is superior when compared to calcineurin inhibitor (CNI) based therapy in “de novo” treated patients and it has also been proposed that individuals at high cardiovascular (CV) risk may benefit most. In this retrospective cohort study, we assessed the efficacy and safety of treating patients at high cardiovascular risk with Belatacept (n = 34, for 1194 observation months) when compared to a matched control group of 150 individuals under CNI immunosuppression (for 7309 months of observation). The estimated glomerular filtration rate (eGFR) increased for patients taking Belatacept but decreased during CNI-based therapy (+2.60 vs. −0.89 mL/min/1.73 m2/year, p = 0.006). In a multivariate Cox regression model, Belatacept remained the only significant factor associated with the improvement of eGFR (HR 4.35, 95%CI 2.39–7.93). Belatacept treatment was not a significant risk factor for renal allograft rejection or graft loss. In terms of safety, the only significant risk factor for de novo cardiovascular events was a pre-existing cerebrovascular disease, but Belatacept was not associated with a significant risk reduction. Belatacept treatment was not associated with an increased risk of severe infections, cytomegalo virus (CMV) or BK-virus reactivation, malignancy or death in the multivariate Cox regression analysis. Belatacept is an efficient and safe option for patients after renal transplantation at high cardiovascular risk.


Sign in / Sign up

Export Citation Format

Share Document